The UK's controversial drug pricing deal with the US is facing legal challenges from campaigners who argue it threatens the independence of the National Institute for Health and Care Excellence (NICE). The deal, announced last December, grants the health secretary the power to override NICE's independent judgment on drug pricing, sparking concerns about the potential for higher drug costs for the NHS. Campaign groups Global Justice Now and Just Treatment have threatened legal action, claiming the move is an 'unlawful power grab'. They argue that the statutory instrument, which came into force last month, undermines NICE's independence, a body respected worldwide for its impartiality. This development has raised alarm among MPs from various parties, who have expressed concern over the secrecy surrounding the deal and the government's refusal to release its impact assessment or engage in parliamentary debate. The legal challenge highlights a deeper question: how can the UK balance the need for access to innovative medicines with the protection of NICE's independence and the interests of NHS patients? The outcome of this legal battle could significantly impact the future of drug pricing and healthcare policy in the UK.
